Pancreatic Cancer Research

ResearcherErasmus MCNo recent work listed

Amber Blaauboer

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0017-0400; OpenAlex author ID A5066804534. Sources: OpenAlex.

Their work

Papers
4
Trials
0
Grants
0
Labs led
0
Collaborators
5
Papers, trials and grants by year

2020: 1 paper · 2021: 1 paper · 2022: 2 papers

Papers 4

  1. The Class I HDAC Inhibitor Valproic Acid Strongly Potentiates Gemcitabine Efficacy in Pancreatic Cancer by Immune System Activation. Co-author DOI 10.3390/biomedicines10030517↗
  2. Immunomodulatory antitumor effect of interferon‑beta combined with gemcitabine in pancreatic cancer. Co-author DOI 10.3892/ijo.2022.5387↗
  3. Type I interferons in pancreatic cancer and development of new therapeutic approaches. Co-author DOI 10.1016/j.critrevonc.2020.103204↗
  4. Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer. Co-author DOI 10.1186/s12885-020-07420-0↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Leo J. Hofland · 4 shared papers, 2020–2022 · strength 0.64
  2. Casper H.J. van Eijck · 4 shared papers, 2020–2022 · strength 0.64
  3. Dana A. M. Mustafa · 2 shared papers, 2022 · strength 0.33
  4. Kostandinos Sideras · 1 shared paper, 2021 · strength 0.19
  5. Stephanie Booy · 1 shared paper, 2020 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.